Contribution of bradykinin to the cardioprotective effects of ACE inhibitors

L. Murphey*, D. Vaughan, N. Brown

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

26 Scopus citations


Bradykinin, through its B2 receptor, stimulates endothelial release of a number of vasodilators, such as nitric oxide, prostacyclin, and endothelium-derived hyperpolarizing factor (EDHF). Angiotensin-converting enzyme (ACE) inhibitors enhance the effects of local bradykinin by decreasing its degradation and by increasing B2 receptor sensitivity. Clinical and experimental studies demonstrate that blockade of the B2 receptor attenuates the antihypertensive, antihypertrophic, and antiatherosclerotic effects of ACE inhibitors. Thus, the evidence strongly supports a role for bradykinin in mediating the cardiovascular benefits of ACE inhibitors.

Original languageEnglish (US)
Pages (from-to)A37-A41
JournalEuropean Heart Journal, Supplement
Issue numberA
StatePublished - Jan 2003


  • ACE inhibitors
  • Bradykinin
  • Endothelial dysfunction
  • Kallikrein-kinin system
  • Ramipril
  • Renin-angiotensin system

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine


Dive into the research topics of 'Contribution of bradykinin to the cardioprotective effects of ACE inhibitors'. Together they form a unique fingerprint.

Cite this